AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Insider Transactions Reported | CARGO Therapeutics(CRGX)saw insider trading activity on 5/16/2025
ByAinvest
Friday, May 16, 2025 6:00 pm ET1min read
CARGO Therapeutics(CRGX) saw insider trading activity on 5/16/2025, there was 1 insider trade during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 5/16/2025 | See Remarks | Radhakrishnan Anup | Sell | 27404 | 3.84 | 105.27k |
| 4/8/2025 | Interim Chief Executive Officer, Chief Financial Officer and Chief Operating Officer | Radhakrishnan Anup | Sell | 1629 | 4.00 | 6.52k |
| 9/20/2024 | President & CEO | Chapman Gina | Sell | 2975 | 25.03 | 74.46k |
| 9/20/2024 | President & CEO | Chapman Gina | Buy | 10141 | 5.03 | 51.01k |
| 9/20/2024 | President & CEO | Chapman Gina | Sell | 7166 | 25.09 | 179.77k |
| 9/20/2024 | Chief Financial Officer | Radhakrishnan Anup | Buy | 1600 | 5.03 | 8.05k |
| 9/20/2024 | Chief Financial Officer | Radhakrishnan Anup | Sell | 1600 | 25.28 | 40.45k |
| 6/3/2024 | -- | Samsara BioCapital GP, LLC | Buy | 294000 | 17.00 | 4998.0k |
| 11/16/2023 | -- | Samsara BioCapital GP, LLC | Buy | 666666 | 15.00 | 9999.99k |
| 11/14/2023 | -- | Third Rock Ventures V, L.P. | Buy | 1333333 | 15.00 | 20000.0k |
[Company Profile]
CARGO Therapeutics, Inc. was incorporated in the state of Delaware in December 2019 as Syncopation Life Sciences, Inc. and changed its name to Cargo Therapeutics, Inc. in September 2022. The company is a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients. The company programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved chimeric antigen receptor T-cell therapies.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet